Article info
PDFPostScript
Letter
Bilateral facial weakness with paraesthesia variant of Guillain-Barré syndrome following Vaxzevria COVID-19 vaccine
- Correspondence to Dr Guendalina Beatrice Bonifacio, Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK; guendalina.bonifacio{at}uhs.nhs.uk
Citation
Bilateral facial weakness with paraesthesia variant of Guillain-Barré syndrome following Vaxzevria COVID-19 vaccine
Publication history
- Received May 5, 2021
- Accepted June 28, 2021
- First published July 14, 2021.
Online issue publication
February 15, 2022
Article Versions
- Previous version (15 February 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage